Concordant and discordant effects on cardiovascular risks exerted by oestrogen and progestogen in women using oral contraception and hormone replacement therapy

P. G. Crosignani, C. La Vecchia

Research output: Contribution to journalArticle

Abstract

The major indications for the clinical use of oestrogen and progestogen are oral contraception (OC) in young women, and hormonal replacement therapy (HRT) in menopause. Over the past few years, epidemiological data have associated the use of these hormones to different cardiovascular conditions such as myocardial infarction, cerebrovascular disease and venous thromboembolism. This review summarizes the data discussed and the conclusions achieved by the ESHRE Capri Workshop Group, recently published in Human Reproduction.

Original languageEnglish
Pages (from-to)681-687
Number of pages7
JournalHuman Reproduction Update
Volume5
Issue number6
Publication statusPublished - Nov 1999

Fingerprint

Cerebrovascular Disorders
Venous Thromboembolism
Hormone Replacement Therapy
Progestins
Menopause
Contraception
Reproduction
Estrogens
Myocardial Infarction
Hormones
Education
Therapeutics

Keywords

  • Cardiovascular risks
  • Hormone replacement
  • Oestrogen
  • Oral contraception
  • Progestogen

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Concordant and discordant effects on cardiovascular risks exerted by oestrogen and progestogen in women using oral contraception and hormone replacement therapy. / Crosignani, P. G.; La Vecchia, C.

In: Human Reproduction Update, Vol. 5, No. 6, 11.1999, p. 681-687.

Research output: Contribution to journalArticle

@article{22052c2bc86944db8ab80163c2e058c9,
title = "Concordant and discordant effects on cardiovascular risks exerted by oestrogen and progestogen in women using oral contraception and hormone replacement therapy",
abstract = "The major indications for the clinical use of oestrogen and progestogen are oral contraception (OC) in young women, and hormonal replacement therapy (HRT) in menopause. Over the past few years, epidemiological data have associated the use of these hormones to different cardiovascular conditions such as myocardial infarction, cerebrovascular disease and venous thromboembolism. This review summarizes the data discussed and the conclusions achieved by the ESHRE Capri Workshop Group, recently published in Human Reproduction.",
keywords = "Cardiovascular risks, Hormone replacement, Oestrogen, Oral contraception, Progestogen",
author = "Crosignani, {P. G.} and {La Vecchia}, C.",
year = "1999",
month = "11",
language = "English",
volume = "5",
pages = "681--687",
journal = "Human Reproduction Update",
issn = "1355-4786",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Concordant and discordant effects on cardiovascular risks exerted by oestrogen and progestogen in women using oral contraception and hormone replacement therapy

AU - Crosignani, P. G.

AU - La Vecchia, C.

PY - 1999/11

Y1 - 1999/11

N2 - The major indications for the clinical use of oestrogen and progestogen are oral contraception (OC) in young women, and hormonal replacement therapy (HRT) in menopause. Over the past few years, epidemiological data have associated the use of these hormones to different cardiovascular conditions such as myocardial infarction, cerebrovascular disease and venous thromboembolism. This review summarizes the data discussed and the conclusions achieved by the ESHRE Capri Workshop Group, recently published in Human Reproduction.

AB - The major indications for the clinical use of oestrogen and progestogen are oral contraception (OC) in young women, and hormonal replacement therapy (HRT) in menopause. Over the past few years, epidemiological data have associated the use of these hormones to different cardiovascular conditions such as myocardial infarction, cerebrovascular disease and venous thromboembolism. This review summarizes the data discussed and the conclusions achieved by the ESHRE Capri Workshop Group, recently published in Human Reproduction.

KW - Cardiovascular risks

KW - Hormone replacement

KW - Oestrogen

KW - Oral contraception

KW - Progestogen

UR - http://www.scopus.com/inward/record.url?scp=0033378757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033378757&partnerID=8YFLogxK

M3 - Article

C2 - 10652978

AN - SCOPUS:0033378757

VL - 5

SP - 681

EP - 687

JO - Human Reproduction Update

JF - Human Reproduction Update

SN - 1355-4786

IS - 6

ER -